Short answer
Bristol Myers Squibb (BMY) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced through Bristol Myers Squibb’s earnings press release.
Bristol Myers Squibb 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced through Bristol Myers Squibb’s earnings press release
- Results furnished under Item 2.02, making the release the primary source for detailed performance metrics
- Disclosure may affect investor expectations for revenue, earnings, guidance, and key product trends
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $12.973B, up 6%; Growth Portfolio $7.560B, up 15%, offsetting Legacy Portfolio decline of 4%
- GAAP EPS $1.62, up 153%; non-GAAP EPS $2.04, up 40%, supported by lower amortization and tax expense
- 2026 revenue guidance raised to approximately $49.0B-$50.0B from $46.0B-$47.5B
- 2026 non-GAAP EPS guidance increased to $6.75-$7.00 from $6.05-$6.35
- Eliquis 2026 worldwide growth outlook raised to 20%-25% from 10%-15%, while operating-expense guidance increased to approximately $16.5B
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bristol Myers Squibb 8-K filings
Get the next BMY 8-K as it lands
Follow BMY for push alerts, or ask the research agent what this filing means.